Pascal Deschatelets - Nov 8, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Stock symbol
APLS
Transactions as of
Nov 8, 2022
Transactions value $
-$508,245
Form type
4
Date filed
11/10/2022, 07:30 AM
Previous filing
Oct 11, 2022
Next filing
Dec 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $49.4K +18.5K +1.93% $2.67* 976K Nov 8, 2022 Direct F1
transaction APLS Common Stock Sale -$558K -12K -1.23% $46.47 964K Nov 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -18.5K -7.72% $0.00 221K Nov 8, 2022 Common Stock 18.5K $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2022.
F2 This stock option was granted on 12/5/2013 and is fully vested.